Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall?

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach, Hareth Nahi, Peter Gimsing, Markus Hansson, Monique C. Minnema, Ulrik Lassen, Jakub Krejcik, Antonio Palumbo, Niels W.C.J. van de Donk, Tahamtan Ahmadi, Imran Khan, Clarissa M. Uhlar, Jianping Wang, A. Kate Sasser, Nedjad Losic, Steen Lisby, Linda Basse, Nikolai Brun, Paul G. Richardson, Targeting CD38 with daratumumab monotherapy in multiple myeloma The New England Journal of Medicine. ,vol. 373, pp. 1207- 1219 ,(2015) , 10.1056/NEJMOA1506348

Jeffrey A. Zonder, Ann F. Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar, Anil K. Singhal, A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma Blood. ,vol. 120, pp. 552- 559 ,(2012) , 10.1182/BLOOD-2011-06-360552

Jesus San Miguel, Katja Weisel, Philippe Moreau, Martha Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Andrew Belch, Antonio Palumbo, Stephen Schey, Pieter Sonneveld, Xin Yu, Lars Sternas, Christian Jacques, Mohamed Zaki, Meletios Dimopoulos, Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial Lancet Oncology. ,vol. 14, pp. 1055- 1066 ,(2013) , 10.1016/S1470-2045(13)70380-2

P. Moreau, J. San Miguel, P. Sonneveld, M.V. Mateos, E. Zamagni, H. Avet-Loiseau, R. Hajek, M.A. Dimopoulos, H. Ludwig, H. Einsele, S. Zweegman, T. Facon, M. Cavo, E. Terpos, H. Goldschmidt, M. Attal, C. Buske, Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. ,vol. 28, pp. 133- 137 ,(2010) , 10.1093/ANNONC/MDX096

Paul G Richardson, Sundar Jagannath, Philippe Moreau, Andrzej J Jakubowiak, Marc S Raab, Thierry Facon, Ravi Vij, Darrell White, Donna E Reece, Lotfi Benboubker, Jeffrey Zonder, L Claire Tsao, Kenneth C Anderson, Eric Bleickardt, Anil K Singhal, Sagar Lonial, Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study The Lancet Haematology. ,vol. 2, ,(2015) , 10.1016/S2352-3026(15)00197-0

Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen, Andrew Belch, Donna Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesus San-Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C. Anderson, Paul Richardson, Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma The New England Journal of Medicine. ,vol. 373, pp. 621- 631 ,(2015) , 10.1056/NEJMOA1505654

Sagar Lonial, Brendan M Weiss, Saad Z Usmani, Seema Singhal, Ajai Chari, Nizar J Bahlis, Andrew Belch, Amrita Krishnan, Robert A Vescio, Maria Victoria Mateos, Amitabha Mazumder, Robert Z Orlowski, Heather J Sutherland, Joan Bladé, Emma C Scott, Albert Oriol, Jesus Berdeja, Mecide Gharibo, Don A Stevens, Richard LeBlanc, Michael Sebag, Natalie Callander, Andrzej Jakubowiak, Darrell White, Javier De La Rubia, Paul G Richardson, Steen Lisby, Huaibao Feng, Clarissa M Uhlar, Imran Khan, Tahamtan Ahmadi, Peter M Voorhees, None, Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial The Lancet. ,vol. 387, pp. 1551- 1560 ,(2016) , 10.1016/S0140-6736(15)01120-4

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa M. Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi, Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Blood. ,vol. 128, pp. 37- 44 ,(2015) , 10.1182/BLOOD-2016-03-705210

Alexander M. Lesokhin, Stephen M. Ansell, Philippe Armand, Emma C. Scott, Ahmad Halwani, Martin Gutierrez, Michael M. Millenson, Adam D. Cohen, Stephen J. Schuster, Daniel Lebovic, Madhav Dhodapkar, David Avigan, Bjoern Chapuy, Azra H. Ligon, Gordon J. Freeman, Scott J. Rodig, Deepika Cattry, Lili Zhu, Joseph F. Grosso, M. Brigid Bradley Garelik, Margaret A. Shipp, Ivan Borrello, John Timmerman, Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase ib study Journal of Clinical Oncology. ,vol. 34, pp. 2698- 2704 ,(2016) , 10.1200/JCO.2015.65.9789

Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo, Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM Blood. ,vol. 127, pp. 2833- 2840 ,(2016) , 10.1182/BLOOD-2016-01-694604